NZ592363A - Anti cxcr4 antibodies and their use for the treatment of cancer - Google Patents
Anti cxcr4 antibodies and their use for the treatment of cancerInfo
- Publication number
- NZ592363A NZ592363A NZ592363A NZ59236309A NZ592363A NZ 592363 A NZ592363 A NZ 592363A NZ 592363 A NZ592363 A NZ 592363A NZ 59236309 A NZ59236309 A NZ 59236309A NZ 592363 A NZ592363 A NZ 592363A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibodies
- cxcr4
- selecting
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 5
- 230000004913 activation Effects 0.000 abstract 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13677208P | 2008-10-01 | 2008-10-01 | |
| EP08305631A EP2172485A1 (en) | 2008-10-01 | 2008-10-01 | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| US17374309P | 2009-04-29 | 2009-04-29 | |
| PCT/EP2009/062787 WO2010037831A1 (en) | 2008-10-01 | 2009-10-01 | Anti cxcr4 antibodies and their use for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592363A true NZ592363A (en) | 2012-08-31 |
Family
ID=40361774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592363A NZ592363A (en) | 2008-10-01 | 2009-10-01 | Anti cxcr4 antibodies and their use for the treatment of cancer |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US8557964B2 (enExample) |
| EP (2) | EP2172485A1 (enExample) |
| JP (1) | JP5723279B2 (enExample) |
| KR (1) | KR101671039B1 (enExample) |
| CN (1) | CN102209730B (enExample) |
| AR (1) | AR073748A1 (enExample) |
| AU (1) | AU2009299787B2 (enExample) |
| BR (1) | BRPI0920531A2 (enExample) |
| CA (1) | CA2738782C (enExample) |
| CL (1) | CL2011000730A1 (enExample) |
| CY (1) | CY1115572T1 (enExample) |
| DK (1) | DK2342233T3 (enExample) |
| ES (1) | ES2503732T3 (enExample) |
| GE (1) | GEP20146084B (enExample) |
| HR (1) | HRP20140899T1 (enExample) |
| IL (1) | IL212066A (enExample) |
| MA (1) | MA32928B1 (enExample) |
| MX (1) | MX2011003509A (enExample) |
| NZ (1) | NZ592363A (enExample) |
| PL (1) | PL2342233T3 (enExample) |
| PT (1) | PT2342233E (enExample) |
| RS (1) | RS53578B1 (enExample) |
| RU (1) | RU2573897C2 (enExample) |
| SI (1) | SI2342233T1 (enExample) |
| TW (1) | TWI469792B (enExample) |
| UA (1) | UA102867C2 (enExample) |
| WO (1) | WO2010037831A1 (enExample) |
| ZA (1) | ZA201102969B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
| EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
| CA2814908A1 (en) * | 2010-10-27 | 2012-05-03 | Pierre Fabre Medicament | Antibodies for the treatment of hiv |
| US20140120555A1 (en) * | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
| ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
| AR087364A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
| AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
| NL2010658C2 (en) * | 2013-04-18 | 2014-10-21 | Bosch Gmbh Robert | Thermostat for a hvac. |
| SG11201600171SA (en) * | 2013-08-02 | 2016-02-26 | Pfizer | Anti-cxcr4 antibodies and antibody-drug conjugates |
| IL305656A (en) | 2013-09-23 | 2023-11-01 | Wilson Wolf Mfg Corporation | Improved methods for genetic modification in animal cells |
| AR104413A1 (es) * | 2015-04-27 | 2017-07-19 | Pf Medicament | Anticuerpo de igf-1r y su utilización para diagnosticar cáncer |
| CN108026173A (zh) | 2015-06-12 | 2018-05-11 | 百时美施贵宝公司 | 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 |
| KR20180094876A (ko) | 2015-11-09 | 2018-08-24 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 에피토프 및 이에 대한 항체 |
| CA3004494A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columiba | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto |
| EP3408378B1 (en) | 2016-01-25 | 2022-01-12 | NantCell, Inc. | Nk cells with altered cxcl12/cxcr4 signaling |
| US10514670B2 (en) * | 2016-05-25 | 2019-12-24 | Kabushiki Kaisha Toshiba | Energy management apparatus, management system, power consumption monitoring method and program |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| CA3052070A1 (en) * | 2017-01-31 | 2018-08-09 | Msm Protein Technologies Inc. | Anti-cxcr4 antibodies |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| WO2019175802A1 (en) | 2018-03-13 | 2019-09-19 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
| CN110804100A (zh) * | 2019-11-01 | 2020-02-18 | 中国人民解放军陆军特色医学中心 | 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN112521500B (zh) * | 2020-12-25 | 2022-06-24 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及应用 |
| CN112661845B (zh) * | 2020-12-25 | 2022-06-21 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及其应用 |
| WO2025049591A1 (en) * | 2023-08-28 | 2025-03-06 | Regeneron Pharmaceuticals, Inc. | Anti-cxcr4 antibodies and uses thereof |
| CN117003876B (zh) * | 2023-08-31 | 2024-06-18 | 恺佧生物科技(上海)有限公司 | 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6949243B1 (en) * | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| US9029097B2 (en) * | 2005-02-16 | 2015-05-12 | Universite De Montreal | Biosensors for monitoring receptor-mediated G-protein activation |
| US8329178B2 (en) * | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| AU2009246683A1 (en) * | 2008-05-14 | 2009-11-19 | Eli Lilly And Company | Anti-CXCR4 antibodies |
-
2008
- 2008-10-01 EP EP08305631A patent/EP2172485A1/en not_active Withdrawn
-
2009
- 2009-09-30 TW TW98133164A patent/TWI469792B/zh not_active IP Right Cessation
- 2009-10-01 PT PT97446454T patent/PT2342233E/pt unknown
- 2009-10-01 AU AU2009299787A patent/AU2009299787B2/en not_active Ceased
- 2009-10-01 KR KR1020117009556A patent/KR101671039B1/ko not_active Expired - Fee Related
- 2009-10-01 CA CA2738782A patent/CA2738782C/en not_active Expired - Fee Related
- 2009-10-01 UA UAA201105412A patent/UA102867C2/uk unknown
- 2009-10-01 WO PCT/EP2009/062787 patent/WO2010037831A1/en not_active Ceased
- 2009-10-01 DK DK09744645.4T patent/DK2342233T3/da active
- 2009-10-01 GE GEAP200912211A patent/GEP20146084B/en unknown
- 2009-10-01 MA MA33784A patent/MA32928B1/fr unknown
- 2009-10-01 AR ARP090103802A patent/AR073748A1/es unknown
- 2009-10-01 SI SI200931016T patent/SI2342233T1/sl unknown
- 2009-10-01 ES ES09744645.4T patent/ES2503732T3/es active Active
- 2009-10-01 EP EP09744645.4A patent/EP2342233B1/en active Active
- 2009-10-01 HR HRP20140899AT patent/HRP20140899T1/hr unknown
- 2009-10-01 PL PL09744645T patent/PL2342233T3/pl unknown
- 2009-10-01 MX MX2011003509A patent/MX2011003509A/es active IP Right Grant
- 2009-10-01 JP JP2011529559A patent/JP5723279B2/ja not_active Expired - Fee Related
- 2009-10-01 RU RU2011115559/10A patent/RU2573897C2/ru not_active IP Right Cessation
- 2009-10-01 NZ NZ592363A patent/NZ592363A/xx not_active IP Right Cessation
- 2009-10-01 BR BRPI0920531-4A patent/BRPI0920531A2/pt not_active IP Right Cessation
- 2009-10-01 RS RSP20140515 patent/RS53578B1/sr unknown
- 2009-10-01 CN CN200980144491.4A patent/CN102209730B/zh not_active Expired - Fee Related
-
2010
- 2010-03-30 US US12/749,891 patent/US8557964B2/en not_active Expired - Fee Related
-
2011
- 2011-03-31 IL IL212066A patent/IL212066A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000730A patent/CL2011000730A1/es unknown
- 2011-04-20 ZA ZA2011/02969A patent/ZA201102969B/en unknown
- 2011-06-23 US US13/167,329 patent/US20110287451A1/en not_active Abandoned
- 2011-06-23 US US13/167,321 patent/US20110294156A1/en not_active Abandoned
-
2013
- 2013-09-13 US US14/025,875 patent/US9388248B2/en not_active Expired - Fee Related
-
2014
- 2014-09-24 CY CY20141100778T patent/CY1115572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ592363A (en) | Anti cxcr4 antibodies and their use for the treatment of cancer | |
| NZ623607A (en) | Anti-gcc antibody molecules and related compositions and methods | |
| CR20200459A (es) | Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl | |
| MX2007006640A (es) | Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina. | |
| NO20084650L (no) | Modifiserte humaniserte anti-interleukin-18 antistoffer | |
| WO2018151836A8 (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
| NO20084480L (no) | Diaryltiohydantoin forbindelser | |
| IL258880A (en) | Diarylhydantoin compounds | |
| EA201100340A1 (ru) | Человеческие антитела, связывающие ген активатор лимфоцитов-3 (lag-3), и их применение | |
| MX2020004119A (es) | Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos. | |
| NO20091841L (no) | Antistoffer mot lymfotoksin-alfa | |
| CY1112739T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης | |
| MY150984A (en) | Anti-agf antibodies | |
| WO2007126799A3 (en) | Compositions and methods of use for antibodies of c-met | |
| WO2009126934A3 (en) | Detection and tratment of pancreatic, ovarian and other cancers | |
| IN2012DN05101A (enExample) | ||
| EA201390744A1 (ru) | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| WO2009015050A3 (en) | Gene expression profile for predicting ovarian cancer patient survival | |
| TW200626900A (en) | Wnt proteins and detection and treatment of cancer | |
| TW200626899A (en) | Frizzled proteins and detection and treatment of cancer | |
| WO2006034328A3 (en) | Wnt proteins and detection and treatment of cancer | |
| WO2006086772A3 (en) | DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS | |
| WO2008118324A3 (en) | Composition and method of treating cancer with an anti-uroplakin ib antibody | |
| ATE491948T1 (de) | Gpr30-östrogenrezeptor bei mammakarzinomen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 OCT 2016 BY ACUMASS Effective date: 20130930 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 OCT 2017 BY ACUMASS Effective date: 20160920 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 OCT 2018 BY ACUMASS Effective date: 20170926 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 OCT 2019 BY ACUMASS Effective date: 20180918 |
|
| LAPS | Patent lapsed |